IVRA yields 17.39% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 8
Combined, IVRA + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IVRA + ABBV for your $10,000?
The Invesco Real Assets ESG ETF (Fund) is an actively-managed exchanged-traded fund that seeks capital appreciation with a secondary objective of current income. The Fund seeks to achieve its investment objective by investing primarily in exchange-traded equity securities of “real assets” companies located in North America that meet high environmental, social and governance (ESG) standards. To meet these standards, the Fund employs a proprietary ESG screening process on all investment opportunities. First, the Fund screens the issuers in the investment universe for exclusions, such as substantial involvement (i.e. generating more than 0-10% of the issuer’s revenue) in tobacco, alcohol, controversial and conventional weapons, recreational cannabis, extraction of thermal coal, extraction of fossil fuels from unconventional sources, and operations of private prisons. Issuers are also excluded based on their non-compliance with the United Nations Global Compact principals. Next, investment opportunities are evaluated on multiple ESG factors under each individual pillar of the ESG framework and real assets sector. The individual pillars include, but are not limited to: environmental pillar (“E”) factors: natural resources, pollution and waste, supply chain impact, and environmental opportunities; social pillar (“S”) factors: workforce, community, product responsibility, and human rights; governance pillar (“G”) factors: management, shareholders, board of directors, auditors, regulatory issuers, corporate social responsibility strategy, anti-corruption, and business ethics. Each ESG pillar and investment opportunity are considered separately and neither weighs each pillar equally, nor consistently emphasizes one pillar over another. “Real assets” are characterized by having physical attributes, including real estate, infrastructure, natural resources and timber. Real assets companies are considered companies that are either principally engaged in real estate, infrastructure, natural resources or timber industries, or support such businesses.Important Notice Regarding Changes to the Fund’s Structure and Management Fee Effective May 13, 2025, The Fund transitioned from a "non-transparent" ETF, which does not publicly disclose its portfolio holdings daily pursuant to an exemptive order from the U.S. Securities and Exchange Commission (the “Order”) to a "transparent" ETF that will disclose its portfolio holdings daily and operate in reliance on Rule 6c-11 under the Investment Company Act of 1940, as amended. In connection with this change to a fully “transparent” structure, the Fund will change as follows:The Fund’s investment objective and principal strategies will remain unchanged despite these structural adjustments and fee reduction.For additional information regarding the unique attributes and risks of the ETF, see the Risk & Other Information section below.
Full IVRA Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.